Potential therapeutic uses of phospholipase A2 inhibitors

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 7, 2004, Pages 937-950

  Clark, James D ^a   Tam, Steve ^a  

^a PFIZER INC   (United States)

Author keywords

Arachidonic acid; Arthritis; Asthma; Atherosclerosis; Inflammation; Inhibitors; Neural injuries; Phospholipase A2; Sepsis

Indexed keywords

4 PYRIMIDINONE DERIVATIVE; ACETAMIDE DERIVATIVE; AMINO ACID DERIVATIVE; ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; BMS 229724; CARBAZOLE DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; DARAPLADIB; HISTIDINE; INDOLE DERIVATIVE; INDOLIZINE DERIVATIVE; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOPROTEIN; LIPOXYGENASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PIPERAZINE DERIVATIVE; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; SECRETORY PROTEIN; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARESPLADIB;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ASTHMA; ATHEROSCLEROSIS; BRAIN INJURY; BRAIN NERVE CELL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENZYME ACTIVITY; GASTROINTESTINAL SYMPTOM; HUMAN; NERVE CELL LESION; NONHUMAN; PATENT; PATHOGENESIS; PROSTAGLANDIN SYNTHESIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; STRUCTURE ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 3543121136     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.7.937     Document Type: Review

References (56)

1. 2 enzymes. Prostaglandins Other Lipid Mediat. (2002) 68-69:3-58.
2. 2 enzymes: classification and characterization. Biochim. Biophys. Acta (2000) 1488:1-19.
3. 2 gene in inbred mouse strains. J. Biol. Chem. (1995) 270:22378-22385.
4. 2 gene is a candidate for the MOM1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell (1995) 81:957.
5. 2 regulation of arachidonic acid mobilization. FEBS Letts (2002) 531:2-6.
6. FUNK CD: Prostaglandins and leukotrienes: advances in eicosanoid biology. Science (2001) 294:1871-1875.
7. PRESCOTT SM, ZIMMERMAN GA, STAFFORINI DM et al.: Platelet-activating factor and related lipid mediators. Ann. Rev. Biochem. (2000) 69:419-445.
8. FITZGERALD GA, PATRONO C: The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. (2001) 345:433-442.
9. JULIUS D, BASBAUM AI: Molecular mechanisms of nociception. Nature (2001) 413:203.
10. WOOLF CJ, SALTER MW: Neuronal plasticity: increasing the gain in pain. Science (2000) 288:1765.
11. DRAZEN JM, ISRAEL E, O'BYRNE PM: Treatment of asthma with drugs modifying the leukotriene pathway. N. Engl. J. Med. (1999) 340:197.
12. MATSUOKA T, HIRATA M, TANAKA H et al.: Prostaglandin D2 as a mediator of allergic asthma. Science (2000) 287(5460):2013-2017.
13. TONUSSI CR, FERREIRA SH: Tumor necrosis factor-α mediates carrageenin-induced knee-joint incapacitation and also triggers overt nociception in previously inflamed rat knee-joints. Int. Assoc. Study Pain (1999) 82:81-87.
14. BENNETT G, AL RASHED S, HOULT JR et al.: Nerve growth factor induced hyperplasis in the rat hind paw is dependent on circulating neutrophils. Int. Assoc. Study Pain (1998) 77:315-322.
15. PIOMELLI D: The ligand that came from within. Trends Pharmacol. Sci (2001) 22:17-29.
16. HONDA Z, ISHII S, SHIMIZU T: Platelet-activating factor receptor. J. Biochem. Tokyo (2002) 131:773-779.
17. 2α-deficient mice are resistant to collagen-induced arthritis. J. Exp. Med. (2003) 10:1297-1302.
18. 2 in allergic response and parturition. Nature (1997) 390:618-622.
19. 2. Nature (1997) 390:622-625.
20. 2 are resistant to MPTP neurotoxicity. J. Neurochem. (1998) 71:2634-2637.
21. 2 suppresses Apc(min)-induced tumorigenesis. Proc. Natl. Acad. Sci. USA (2001) 98(7):3935-3939.
22. 2 gene. J. Biol. Chem. (2000) 275(44):34013-34016.
23. 2 as revealed by gene-targeted mice. Prostaglandins Other Lipid Mediat. (2002) 68-69:59-69.
24. MORHAM SG, LANGENBACH R, LOFTIN CD et al.: Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell (1995) 83:473-482.
25. KOMKOFF M, WANG JL, CHENG HF et al.: Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int. (2000) 57:414-422.
26. LIM H, PARIA BC, DAS S et al.: Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell (1997) 91:197-208.
27. FITZGERALD GA: Cox-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov. (2003) 2:879-890.
28. VANE JR: Back to an aspirin a day? Science (2002) 296:474-475.
29. MUKHERJEE D, NISSEN S, TOPOL E: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA (2001) 286:954-959.
30. BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. (2000) 343:1520-1528.
31. SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al.: Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA (2000) 284:1247-1255.
32. WALLACE JL: NSAID gastroenteropathy: past, present, and future. Can. J. Gastroenterol. (1996) 10:451-459.
33. HELGADOTTIR A, MANOLESCU A, THORLEIFSSON G et al.: The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat. Genetics (2004) 36(3):233-239.
34. 4 receptor antagonism reduces monocytic foam cells in mice. Artherioscler. Throm. Vasc. Biol. (2002) 22(3):443-449.
35. TEW DG, SOUTHAN C, RICE SQ et al.: Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins. Arterioscler. Throm. Vasc. Biol. (1996) 16:591-599.
36. 2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curr. Opin. Lipidol. (2003) 14:347-352.
37. 2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis (2003) 168:283-288.
38. 2 in vascular disease. Circ. Res. (2001) 89:298-304.
39. 2-paradigm. Chem. Rev. (2001) 101:2613-2653.
40. 2 inhibitors in inflammation. Expert Opin. Ther. Patents (2001) 11(7):1123-1136.
41. 2 on short chain phosphaditylcholine-mixed micelles: development of a spectrophotometric assay suitable for a microtiterplate assay. Anal. Biochem. (1992) 204(1 ):190-197.
42. 2 inhibitor a new class of anti-inflammatory drugs, SPI. J. Pharm. Exp. Therap. (1999) 288:1117-1124.
43. 2, in patients with suspected sepsis and organ failure. Crit. Care Med. (2003) 31(3):718-728.
44. 2 inhibitor in patients with severe sepsis. Mediators Inflamm. (1999) 8(Suppl. 1):8.
45. SCRIP Daily Online: S00812424 (13/08/03).
46. 2. J. Med. Chem. (1994) 37(5):557-559.
47. 2. Anal. Biochem. (1994) 222:110-115.
48. 2s in human neutrophils. J. Biol. Chem (2002) 277:5061-5073.
49. 2α inhibitors. 226th ACS National Meeting, New York, NY, USA (2003) MEDI 203.
50. 2. Biochemistry (1995) 34:15165-15174.
51. 2 that acts at the lipid/water interface and possesses anti-inflammatory activity in the skin inflammation. J. Pharm. Exp. Therap. (2001) 298:376-385.
52. 2 based on a 1,3-disubstituted propan-2-one skeleton. J. Med. Chem. (2002) 45:1348-1362.
53. 2. J. Med. Chem. (2002) 45:2891-2893.
54. 2 platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. (1999) 338:479-487.
55. 2. Bioorg. Med. Chem. Lett. (2001) 11:1925-1929.
56. 2. Bioorg. Med. Chem. Lett. (2003) 13:1067-1070.